Personalized medicine is transforming PD care, moving beyond generic treatments to tailor therapies to genetic and symptom profiles. This shift enhances efficacy and reshapes the PD therapeutics market, as firms invest in tools to identify patient subgroups.

Genetic testing (LRRK2, GBA mutations) guides targeted therapies. Only 20% of high-income PD patients test genetically (2023 AJN study). Market Research Future’s Personalized Medicine in Parkinson’s Treatment analysis explores adoption barriers and market opportunities.

Symptom profiling uses digital biomarkers (wearables, AI trackers) to capture variability. A German 2024 AI pilot improved treatment response by 25%. These tools aid clinicians and firms in designing targeted trials, reducing failures and costs.

Challenges include testing costs and LMIC access, yet FDA’s 2023 approval of a mutation-targeted drug with companion diagnostics sets a precedent. Personalized medicine is projected to capture 18% of PD market revenue by 2028, driving innovation and better patient outcomes.